Please login to the form below

Not currently logged in
Email:
Password:

NICE to retain powers

As part of changes announced to the UK government's Health and Social Care Bill, the National Institute of Health and Clinical Excellence is to retain its responsibility to recommend drugs and treatments for use on the NHS

As part of changes announced to the UK government's Health and Social Care Bill following recommendations from the Future Forum group of healthcare experts, the National Institute of Health and Clinical Excellence (NICE) is to retain its responsibility to recommend drugs and treatments for use on the NHS.

In its list of core changes (pdf), the UK's Department of Health (DH) confirmed patients will have "the right to drugs and treatments recommended by NICE, which we will retain after the introduction of value-based pricing for new drugs from January 2014."

Original suggestions outlined in the Bill regarding NICE's role proposed that the agency would only appraise new products rather than make recommendations for their use.

Sir Andrew Dillon, chief executive of NICE, said: "We are pleased to see that NICE will continue to play a key role in helping to ensure that patients receive the best possible care on the NHS."

"We look forward to engaging with clinical commissioning groups and to supporting their work through the use of our guidelines, quality standards and commissioning guides."

As reported in the Financial Times (FT), NICE chairman, Sir Michael Rawlins said the changes to the Bill would be welcomed by GPs, with doctors wary of damaging patient relationships if they were the ones to make a decision about whether a drug is cost-effective or not.

"They wanted a 'blame quango' to be responsible – ie. NICE," said Rawlins, according to the FT.

20th June 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics